Results 161 to 170 of about 117,026 (248)

Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance. [PDF]

Int J Mol Sci, 2022
Fuentes-Fayos AC, G-García ME, Pérez-Gómez JM, Peel A, Blanco-Acevedo C, Solivera J, Ibáñez-Costa A, Gahete MD, Castaño JP, Luque RM.   +9 more
europepmc   +1 more source

The significance of new somatostatin analogs as therapeutic agents

, 2009
The effects of somatostatin, or somatotropin release-inhibiting factor (SRIF), and SRIF analogs in human diseases have been widely investigated to potentially expand the therapeutic applications of commercially available and newly designed compounds ...
ZATELLI, Maria Chiara, DEGLI UBERTI, Ettore   +1 more
core  

Synthetic somatostatin analogs beyond cancer. [PDF]

Pituitary
Barabutis N, Siejka A.
europepmc   +1 more source

Somatostatin analogs in the clinical management of pituitary neoplasms

, 2001
The medical approach to patients with secreting or clinically non-functioning pituitary adenoma as made considerable progress thanks to the use of new somatostatin analogs.
Auriemma RS, Colao A, ROSSI, FRANCESCA WANDA, Lastoria S., Dorato M, Pulcrano M, Lombardi G   +6 more
core  

Somatostatin Analogs for Preventing Postoperative Pancreatic Fistula: Past Evidence Reveals New Opportunities. [PDF]

Ann Surg Oncol
Goodsell KE, Chauhan SSB, Pillarisetty VG, Sham JG.   +3 more
europepmc   +1 more source

"Cold" Somatostatin Analogs in Neuroendocrine Neoplasms: Decoding Mechanisms, Overcoming Resistance, and Shaping the Future of Therapy. [PDF]

Cells
Massironi S, Albertelli M, Hasballa I, Paravani P, Ferone D, Faggiano A, Danese S.   +6 more
europepmc   +1 more source

Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors. [PDF]

J Neuroendocrinol
Santo G, di Santo G, Cicone F, Virgolini I.   +3 more
europepmc   +1 more source

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. [PDF]

Endocrine, 2021
Kuhn E, Caron P, Delemer B, Raingeard I, Lefebvre H, Raverot G, Cortet-Rudelli C, Desailloud R, Geffroy C, Henocque R, Brault Y, Brue T, Chanson P.   +12 more
europepmc   +1 more source

Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs. [PDF]

J Neuroendocrinol
Polici M, Caruso D, Masci B, Marasco M, Valanzuolo D, Dell'Unto E, Zerunian M, Campana D, De Santis D, Lamberti G, Iannicelli E, Prosperi D, Annibale B, Laghi A, Panzuto F, Rinzivillo M.   +15 more
europepmc   +1 more source

The role of somatostatin analogs in the management of immunoproliferative disease.

, 2003
The role of somatostatin analogs in the management of immunoproliferative ...
Semino C, Minuto F., Barreca A, PIVONELLO, ROSARIO, FERONE, DIEGO, Arvigo M, van Hagen PM   +6 more
core